HISOAR(SZ:002099)2020-08-26 16:00Financial Performance - Zhejiang Hisoar Pharmaceutical Co., Ltd. reported a revenue of CNY 1.2 billion for the first half of 2020, representing a year-on-year increase of 15%[19]. - The company's net profit attributable to shareholders reached CNY 200 million, up 10% compared to the same period last year[19]. - The company anticipates a revenue growth forecast of 20% for the full year 2020, driven by new product launches and market expansion efforts[19]. - The company's operating revenue for the first half of 2020 was ¥1,307,832,289.16, a decrease of 24.51% compared to ¥1,732,533,807.60 in the same period last year[26]. - Net profit attributable to shareholders was ¥265,595,667.92, down 46.43% from ¥495,793,061.64 year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥253,524,072.02, a decline of 47.51% compared to ¥482,987,643.81 in the previous year[26]. - The net cash flow from operating activities increased by 12.67% to ¥342,431,067.66 from ¥303,913,948.74 in the same period last year[26]. - Basic and diluted earnings per share were both ¥0.16, a decrease of 50.00% from ¥0.32 year-on-year[26]. - The weighted average return on equity was 4.79%, down 4.38 percentage points from 9.17% in the previous year[26]. - The company reported a decrease in sales orders due to the COVID-19 pandemic, resulting in lower sales volume and prices for dye products compared to the same period last year[86]. Market Expansion and Product Development - User data indicates a growth in the customer base by 20%, with significant increases in both domestic and international markets[19]. - The company plans to launch three new products in the second half of 2020, targeting a market expansion of 25% in the pharmaceutical sector[19]. - The company has outlined a strategic goal to enter two new international markets by the end of 2021, aiming for a 30% increase in overseas sales[19]. - The pharmaceutical segment includes a range of products for various applications, including antibiotics and cardiovascular drugs, with significant certifications from multiple countries[36][40]. - The pharmaceutical segment generated revenue of 822 million yuan, a decline of 12.11%, while the dye segment reported revenue of 486 million yuan, down 39.09%[48]. - The company expanded its CDMO/CMO business, achieving over 100 million yuan in sales revenue during the first half of 2020, with more than ten commercial cooperation projects underway[48]. - R&D investment exceeded 60 million yuan, with 25 projects under development, including 15 pharmaceutical projects[48]. Financial Management and Investments - Zhejiang Hisoar has no plans to distribute cash dividends or issue bonus shares for the current fiscal year, focusing instead on reinvestment[7]. - The total investment during the reporting period was ¥143,498,321.76, a decrease of 39.76% compared to the previous year[63]. - The total amount of raised funds is RMB 101,440.36 million, with RMB 1,634.51 million invested during the reporting period[67]. - Cumulative investment of raised funds reached RMB 46,354.81 million, with a cumulative change in purpose amounting to RMB 37,061.61 million, representing 36.54% of the total raised funds[67]. - The company received bank deposit interest of RMB 23,750.33 million and wealth management product income of RMB 29,628.79 million cumulatively[67]. Risk Management and Compliance - Risk management strategies have been implemented to address potential market fluctuations and regulatory changes[7]. - The company has implemented measures to address environmental compliance risks, which may increase operational costs[90]. - The company has passed 11 official inspections and 10 customer/third-party audits during the reporting period, ensuring compliance with quality management systems[48]. - The company has a comprehensive emergency response plan for environmental incidents, including training for employees[142]. - The company has reported no significant environmental violations during the reporting period[143]. Shareholder and Corporate Governance - The company has implemented a 2020 employee stock ownership plan to align the interests of employees and shareholders, promoting long-term stability[51]. - The company has committed to avoiding any competitive business activities with its subsidiaries during the holding period of shares[99]. - The company will ensure that any unavoidable related transactions are conducted at fair market prices and in compliance with legal procedures[99]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[166]. - There were changes in the management team, with the appointment of a new general manager and financial director in May and July 2020, respectively[179]. Environmental Impact - The company has constructed multiple wastewater, waste gas, and solid waste treatment facilities to reduce pollutant emissions[142]. - The total COD emissions for Zhejiang Haixiang Pharmaceutical Co., Ltd. were reported at 3.49 tons and ammonia nitrogen emissions of 0.1 tons, with no exceedance of discharge standards[135]. - The total VOCs emissions for Zhejiang Haixiang Pharmaceutical Co., Ltd. were reported at 12.42 tons per year, within the approved discharge limits[135]. - The company has established a new subsidiary, Zhejiang Qilian Environmental Technology Co., Ltd., with a registered capital of 100 million yuan, focusing on hazardous waste management[149].